RecruitingNot ApplicableNCT07419633

This Study Investigates β-hydroxy-β-methylbutyrate (HMB) and 2-hydroxybenzylamine (2-HOBA), When Administered Either Individually or in Combination Contributes to an Increased Quality of Health, Specifically Improving Muscular Strength and Cognitive Functioning in Adults Over the Age of 65.

The Effects of Beta-Hydroxy-Beta-methylbutyrate (HMB) and/or 2-hydroxybenzylamine (2-HOBA) on Markers of Health Span in Older Adults. A Randomized Control Trial.


Sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Enrollment

120 participants

Start Date

Mar 6, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

In this study, participants will be assigned to receive HMB, 2-HOBA, a combination of both, or a comparison supplement for a set period of time. During the study, participants will attend scheduled visits where researchers will assess muscle strength, physical function, and overall health. Blood samples may be collected to measure markers related to metabolism, inflammation, and oxidative stress. Study staff will also monitor safety and any side effects throughout the study.


Eligibility

Min Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying 2-hydroxybenzylamine, Placebo, and others for people with ageing and geriatric health, cognitive functioning, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 65 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTβ-Hydroxy-β-methylbutyrate

Participants in intervention group HMB (H) will receive HMB supplementation at a dose of 3g/day, consisting of 2 tablets of 750mg each, twice daily for a period of 90 days.

DIETARY_SUPPLEMENT2-hydroxybenzylamine

Participants in the intervention group (2-H) will receive 2-HOBA at a dose of 650mg/day, respectively consisting of 2 tablets of 162.5mg each, twice daily for a period of 90 days.

DIETARY_SUPPLEMENTβ-Hydroxy-β-methylbutyrate and 2-hydroxybenzylamine

Participants in the intervention group (H-2-H) will receive HMB + 2-HOBA at a dose of 3g and 650 mg/day, respectively, consisting of 2 tablets of 750mg and 325mg each, twice daily for a period of 90 days.

DIETARY_SUPPLEMENTPlacebo

Participants in control group (c) will receive 2 tablets- twice daily, each containing the same ingredients, placebo will be identical color and weight matched tablets with excipients (no HMB and no 2-HOBA) for a period of 90 days.


Locations(1)

RI-MUHC

Montreal, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07419633


Related Trials